Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28287282 | 0.98 | L3MBTL1 (0.41) | L3MBTL1NFE2L2PTK2GRM4POLB | |
| SCHEMBL1465207 | 0.80 | NFE2L2 (0.42) | L3MBTL1NFE2L2PTK2GRM4POLB | |
| SCHEMBL2704697 | 0.78 | CA1 (0.61) | L3MBTL1NFE2L2POLBKDM4EADRA2A | |
| SCHEMBL2645976 | 0.78 | NFE2L2 (0.41) | L3MBTL1NFE2L2PTK2GRM4POLB | |
| SCHEMBL8847357 | 0.76 | KDM4E (0.61) | L3MBTL1POLBKDM4ECA12CA1 | |
| SCHEMBL8119449 | 0.76 | LMNA (0.44) | KDM4ECA12CA1CA2CA9 | |
| SCHEMBL27326807 | 0.75 | NFE2L2 (0.39) | L3MBTL1NFE2L2PTK2GRM4POLB | |
| SCHEMBL19868461 | 0.75 | KDM4E (0.41) | L3MBTL1NFE2L2GRM4POLBKDM4E | |
| SCHEMBL30727325 | 0.75 | NFE2L2 (0.39) | L3MBTL1NFE2L2PTK2GRM4POLB | |
| SCHEMBL1657082 | 0.75 | KDM4E (0.41) | L3MBTL1NFE2L2PTK2POLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101238106-B | Fluoro substituted 2-oxo azepan derivatives | HOFFMANN LA ROCHE | 2011-02-16 | — | — | CN | disclosed |
| EP-1915345-B1 | FLUORO SUBSTITUTED 2-OXO AZEPAN DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-12-22 | — | — | EP | disclosed |
| US-7501406-B2 | Fluoro substituted 2-oxo-azepan derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | disclosed |
| CN-101238106-A | Fluoro substituted 2-oxo azepan derivatives | HOFFMANN LA ROCHE (CH) | 2008-08-06 | — | — | CN | disclosed |
| EP-1915345-A1 | FLUORO SUBSTITUTED 2-OXO AZEPAN DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007020190-A1 | FLUORO SUBSTITUTED 2-OXO AZEPAN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037789-A1 | 4-chloro-N-((R)-5,5-difluoro-2-oxo-azepan-3-yl)-N-[2-fluoro-4-(2H-[1,2,4]triazol-3-yl)-benzyl]-benzenesulfonamide; gamma -secretase inhibitor; neurodegenerative diseases; Alzheimer's disease; anticarcinogenic agent; cervical carcinomas and breast carcinomas and malignancies of the hematotic system | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037789-A1 | 4-chloro-N-((R)-5,5-difluoro-2-oxo-azepan-3-yl)-N-[2-fluoro-4-(2H-[1,2,4]triazol-3-yl)-benzyl]-benzenesulfonamide; gamma -secretase inhibitor; neurodegenerative diseases; Alzheimer's disease; anticarcinogenic agent; cervical carcinomas and breast carcinomas and malignancies of the hematotic system | BACE1, BACE2, BRCA1 | L3MBTL1 2036/4885NFE2L2 557/4885PTK2 2871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.